MSFT 414.2 2.0901% AAPL 220.11 -0.3621% NVDA 108.1 1.5309% GOOGL 148.66 -0.0336% GOOG 150.01 0.3143% AMZN 179.55 2.366% META 504.79 0.0% AVGO 148.21 5.2478% TSLA 226.17 4.5776% TSM 162.43 -0.215% LLY 901.25 -0.7729% V 285.34 -0.0945% JPM 205.56 -5.1889% UNH 599.03 0.8298% NVO 129.78 -1.6147% WMT 78.81 1.9007% LVMUY 135.45 -0.7401% XOM 110.82 -3.6432% LVMHF 676.0 -1.0402% MA 488.02 0.1909%
Last update at 2024-09-11T00:10:00Z
Ashland Wraps Up Nutraceuticals Business Sale to Turnspire Affiliate
Wed 04 Sep 24, 10:39 AMAshland Inc. (ASH): Strong Performance with 20.64% Upside Potential in Specialty Chemicals
Mon 02 Sep 24, 02:04 AMHere's Why Ashland (ASH) is a Strong Value Stock
Fri 23 Aug 24, 01:40 PMAshland (NYSE:ASH) Will Pay A Dividend Of $0.405
Thu 15 Aug 24, 11:13 AMAshland board authorizes quarterly dividend
Fri 09 Aug 24, 09:01 PMASH vs. NVZMY: Which Stock Should Value Investors Buy Now?
Thu 08 Aug 24, 03:40 PMAshland Third Quarter 2024 Earnings: Misses Expectations
Thu 08 Aug 24, 11:24 AMWhy Ashland (ASH) is a Top Value Stock for the Long-Term
Wed 07 Aug 24, 01:40 PMAshland's (ASH) Earnings Beat Estimates in Q3, Sales Lag
Wed 07 Aug 24, 10:55 AM| Breakdown | 2023-09-30 | 2022-09-30 | 2021-09-30 | 2020-09-30 | 2019-09-30 |
|---|---|---|---|---|---|
| Type | yearly | yearly | yearly | yearly | yearly |
| Date | 2023-09-30 | 2022-09-30 | 2021-09-30 | 2020-09-30 | 2019-09-30 |
| Income before tax | 160.00M | 206.00M | 135.00M | -503.00000M | 70.00M |
| Minority interest | - | - | - | - | 0.00000M |
| Net income | 178.00M | 181.00M | 173.00M | -491.00000M | 24.00M |
| Selling general administrative | 307.00M | 393.00M | 358.00M | 424.00M | 539.00M |
| Selling and marketing expenses | - | - | - | - | - |
| Gross profit | 668.00M | 830.00M | 670.00M | 707.00M | 767.00M |
| Reconciled depreciation | 243.00M | 241.00M | 244.00M | 247.00M | 289.00M |
| Ebit | 160.00M | 246.00M | 181.00M | 662.00M | 166.00M |
| Ebitda | 403.00M | 487.00M | 405.00M | 909.00M | 453.00M |
| Depreciation and amortization | 243.00M | 241.00M | 224.00M | 247.00M | 287.00M |
| Non operating income net other | - | - | 11.00M | 2.00M | - |
| Operating income | 172.00M | 246.00M | 181.00M | 662.00M | 166.00M |
| Other operating expenses | 2032.00M | 2103.00M | 1939.00M | 2192.00M | 2331.00M |
| Interest expense | 6.00M | 62.00M | 69.00M | 88.00M | 99.00M |
| Tax provision | -8.00000M | 25.00M | -38.00000M | -12.00000M | 17.00M |
| Interest income | 6.00M | 149.00M | 56.00M | 57.00M | 95.00M |
| Net interest income | -6.00000M | -149.00000M | -56.00000M | -119.00000M | -116.00000M |
| Extraordinary items | 10.00M | 746.00M | 47.00M | -17.00000M | 452.00M |
| Non recurring | - | - | - | 530.00M | - |
| Other items | - | - | - | - | - |
| Income tax expense | -8.00000M | 25.00M | -38.00000M | -12.00000M | 46.00M |
| Total revenue | 2191.00M | 2391.00M | 2111.00M | 2326.00M | 2493.00M |
| Total operating expenses | 509.00M | 542.00M | 498.00M | 573.00M | 605.00M |
| Cost of revenue | 1523.00M | 1561.00M | 1441.00M | 1619.00M | 1726.00M |
| Total other income expense net | 7.00M | -40.00000M | -46.00000M | -1165.00000M | -96.00000M |
| Discontinued operations | - | 746.00M | 47.00M | -17.00000M | 481.00M |
| Net income from continuing ops | 168.00M | 181.00M | 173.00M | -491.00000M | 24.00M |
| Net income applicable to common shares | 178.00M | 927.00M | 220.00M | -508.00000M | 505.00M |
| Preferred stock and other adjustments | - | - | - | - | - |
| Breakdown | 2023-09-30 | 2022-09-30 | 2021-09-30 | 2020-09-30 | 2019-09-30 |
|---|---|---|---|---|---|
| Type | yearly | yearly | yearly | yearly | yearly |
| Date | 2023-09-30 | 2022-09-30 | 2021-09-30 | 2020-09-30 | 2019-09-30 |
| Total assets | 5939.00M | 6213.00M | 6612.00M | 6877.00M | 7251.00M |
| Intangible assets | 886.00M | 963.00M | 1099.00M | 1013.00M | 1088.00M |
| Earning assets | - | - | - | - | - |
| Other current assets | 125.00M | 91.00M | 68.00M | 87.00M | 64.00M |
| Total liab | 2842.00M | 2993.00M | 3860.00M | 3841.00M | 3680.00M |
| Total stockholder equity | 3097.00M | 3220.00M | 2752.00M | 3036.00M | 3571.00M |
| Deferred long term liab | - | 2.00M | 237.00M | 229.00M | 4.00M |
| Other current liab | 208.00M | 269.00M | 50.00M | 277.00M | 7.00M |
| Common stock | - | 1.00M | 1.00M | 1.00M | 1.00M |
| Capital stock | - | 1.00M | 1.00M | 1.00M | 1.00M |
| Retained earnings | - | 3653.00M | 2796.00M | 2649.00M | 3224.00M |
| Other liab | - | 1076.00M | 1220.00M | 1331.00M | 1422.00M |
| Good will | 1362.00M | 1312.00M | 1430.00M | 1758.00M | 2253.00M |
| Other assets | 563.00M | 725.00M | 815.00M | 994.00M | 888.00M |
| Cash | 417.00M | 646.00M | 210.00M | 454.00M | 232.00M |
| Cash and equivalents | 417.00M | 646.00M | 210.00M | 454.00M | 232.00M |
| Total current liabilities | 456.00M | 553.00M | 934.00M | 813.00M | 757.00M |
| Current deferred revenue | - | - | 251.00M | 26.00M | 271.00M |
| Net debt | 1041.00M | 737.00M | 1893.00M | 1546.00M | 1435.00M |
| Short term debt | 38.00M | 19.00M | 397.00M | 303.00M | 166.00M |
| Short long term debt | 16.00M | - | 374.00M | 280.00M | 166.00M |
| Short long term debt total | 1458.00M | 1383.00M | 2103.00M | 2000.00M | 1667.00M |
| Other stockholder equity | 3097.00M | 135.00M | 327.00M | 769.00M | 756.00M |
| Property plant equipment | 1495.00M | 1445.00M | 1427.00M | 1565.00M | 1577.00M |
| Total current assets | 1506.00M | 1768.00M | 1717.00M | 1547.00M | 1433.00M |
| Long term investments | - | 3.00M | 134.00M | 136.00M | 6.00M |
| Net tangible assets | - | 945.00M | 223.00M | 265.00M | 224.00M |
| Short term investments | - | - | - | - | - |
| Net receivables | 338.00M | 402.00M | 369.00M | 471.00M | 481.00M |
| Long term debt | 1314.00M | 1270.00M | 1596.00M | 1573.00M | 1501.00M |
| Inventory | 626.00M | 629.00M | 473.00M | 529.00M | 597.00M |
| Accounts payable | 210.00M | 265.00M | 236.00M | 233.00M | 313.00M |
| Total permanent equity | - | - | - | - | - |
| Noncontrolling interest in consolidated entity | - | - | - | - | - |
| Temporary equity redeemable noncontrolling interests | - | - | - | - | - |
| Accumulated other comprehensive income | - | -569.00000M | -372.00000M | -383.00000M | -410.00000M |
| Additional paid in capital | - | - | - | - | - |
| Common stock total equity | - | 1.00M | 1.00M | 1.00M | 1.00M |
| Preferred stock total equity | - | - | - | - | - |
| Retained earnings total equity | - | 3653.00M | 2796.00M | 2649.00M | - |
| Treasury stock | - | - | - | - | - |
| Accumulated amortization | - | - | - | - | - |
| Non currrent assets other | 541.00M | 702.00M | 781.00M | 826.00M | 567.00M |
| Deferred long term asset charges | - | - | - | - | - |
| Non current assets total | 4433.00M | 4445.00M | 4895.00M | 5330.00M | 5818.00M |
| Capital lease obligations | 128.00M | 113.00M | 133.00M | 147.00M | - |
| Long term debt total | 1314.00M | 1270.00M | 1596.00M | 1573.00M | 1501.00M |
| Breakdown | 2023-09-30 | 2022-09-30 | 2021-09-30 | 2020-09-30 | 2019-09-30 |
|---|---|---|---|---|---|
| Type | yearly | yearly | yearly | yearly | yearly |
| Date | 2023-09-30 | 2022-09-30 | 2021-09-30 | 2020-09-30 | 2019-09-30 |
| Investments | -109.00000M | 1556.00M | 1.00M | 8.00M | 849.00M |
| Change to liabilities | - | 34.00M | 3.00M | -50.00000M | -79.00000M |
| Total cashflows from investing activities | -109.00000M | 1556.00M | -367.00000M | -90.00000M | 849.00M |
| Net borrowings | - | -615.00000M | 101.00M | 82.00M | -875.00000M |
| Total cash from financing activities | -371.00000M | -896.00000M | -426.00000M | 9.00M | -1149.00000M |
| Change to operating activities | - | -247.00000M | 80.00M | -3.00000M | -84.00000M |
| Net income | 178.00M | 927.00M | 220.00M | -508.00000M | 505.00M |
| Change in cash | -229.00000M | 436.00M | -244.00000M | 222.00M | -62.00000M |
| Begin period cash flow | 646.00M | 210.00M | 454.00M | 232.00M | 294.00M |
| End period cash flow | 417.00M | 646.00M | 210.00M | 454.00M | 232.00M |
| Total cash from operating activities | 243.00M | -213.00000M | 560.00M | 203.00M | 241.00M |
| Issuance of capital stock | - | - | - | - | - |
| Depreciation | 243.00M | 241.00M | 244.00M | 247.00M | 289.00M |
| Other cashflows from investing activities | 61.00M | 1618.00M | -277.00000M | 146.00M | 996.00M |
| Dividends paid | -76.00000M | -70.00000M | -70.00000M | -66.00000M | 64.00M |
| Change to inventory | -141.00000M | -141.00000M | 41.00M | 65.00M | -4.00000M |
| Change to account receivables | -23.00000M | -23.00000M | 72.00M | 7.00M | 38.00M |
| Sale purchase of stock | -300.00000M | -200.00000M | -450.00000M | 0.00000M | -200.00000M |
| Other cashflows from financing activities | 5.00M | -376.00000M | -13.00000M | 901.00M | -10.00000M |
| Change to netincome | - | -1141.00000M | 8.00M | 430.00M | -398.00000M |
| Capital expenditures | 170.00M | 113.00M | 105.00M | 138.00M | 154.00M |
| Change receivables | - | - | - | - | - |
| Cash flows other operating | - | -236.00000M | 81.00M | 19.00M | - |
| Exchange rate changes | - | - | 3.00M | 2.00M | - |
| Cash and cash equivalents changes | - | -805.00000M | -324.00000M | 234.00M | - |
| Change in working capital | -58.00000M | -247.00000M | 80.00M | 19.00M | -129.00000M |
| Stock based compensation | 22.00M | 18.00M | 15.00M | 14.00M | 21.00M |
| Other non cash items | -110.00000M | -1127.00000M | 27.00M | 474.00M | -465.00000M |
| Free cash flow | 73.00M | -326.00000M | 455.00M | 65.00M | 87.00M |
Sector: Basic Materials Industry: Specialty Chemicals
| Company | Change (USD) | Price (USD) | Trailing PE (x) | Forward PE (x) | Price Sales TTM (x) | Price to Book Value (x) | Enterprise Value to Revenue (x) | Enterprise Value to EBITDA (x) |
|---|---|---|---|---|---|---|---|---|
| ASH Ashland Global Holdings Inc |
-0.86 1.01% | 84.50 | 27.24 | 19.19 | 1.96 | 1.39 | 2.44 | 11.69 |
| LIN Linde plc Ordinary Shares |
0.64 0.14% | 463.72 | 33.77 | 28.90 | 6.56 | 5.42 | 7.03 | 18.92 |
| AIQUY Air Liquide SA ADR |
0.61 1.66% | 37.25 | 29.34 | 24.57 | 3.42 | 3.95 | 3.87 | 15.91 |
| AIQUF L'Air Liquide S.A |
- -% | 187.21 | 29.39 | 24.69 | 3.41 | 3.97 | 3.87 | 15.91 |
| SHW Sherwin-Williams Co |
7.95 2.18% | 371.85 | 33.33 | 27.40 | 3.38 | 20.60 | 3.88 | 21.36 |
Ashland Inc. provides additives and specialty ingredients in the North and Latin America, Europe, Asia Pacific, and internationally. It operates through Life Sciences, Personal Care, Specialty Additives, and Intermediates segments. The Life Sciences segment offers pharmaceutical solutions, including controlled release polymers, disintegrants, tablet coatings, thickeners, solubilizers, and tablet binders; nutrition solutions, such as thickeners, stabilizers, emulsifiers, and additives; and nutraceutical solutions comprising products for weight management, joint comfort, stomach and intestinal health, sports nutrition, and general wellness, as well as custom formulation, toll processing, and particle engineering solutions. Its Personal Care segment provides a range of nature-based, biodegradable, and performance ingredients; solutions for toothpastes, mouth washes and rinses, denture cleaning, and care for teeth; and household supplies nature-derived rheology ingredients, biodegradable surface wetting agents, performance encapsulates, and specialty polymers. The Specialty Additives segment offers rheology modifiers, foam control agents, surfactants and wetting agents, pH neutralizers, advanced ceramics used in catalytic converters, environmental filters, ingredients for the manufacturing of ceramic capacitors, plasma display panels and solar cells, ingredients for textile printing, thermoplastic metals, and alloys for welding. Its Intermediates segment produces 1,4 butanediol and related derivatives, including n-methylpyrrolidone. It offers its products to customers in a range of consumer and industrial markets, such as architectural coatings, construction, energy, food and beverage, nutraceuticals, personal care, and pharmaceutical. The company was formerly known as Ashland Global Holdings Inc. and changed its name to Ashland Inc. in August 2022. Ashland Inc. was founded in 1924 and is headquartered in Wilmington, Delaware.
8145 Blazer Drive, Wilmington, DE, United States, 19808
| Name | Title | Year Born |
|---|---|---|
| Mr. Guillermo Novo | Chairman & CEO | 1962 |
| Mr. John Kevin Willis | Sr. VP & CFO | 1965 |
| Dr. Osama M. Musa | Sr. VP & CTO | 1968 |
| Mr. Min S. Chong | Sr. VP & GM of Specialty Additives and Intermediates and Solvents | 1971 |
| Mr. Ashok S. Kalyana | Sr. VP & GM of Life Sciences | 1972 |
| Mr. Eric N. Boni | VP of Fin. & Principal Accounting Officer | 1969 |
| Seth A. Mrozek | Director of Investor Relations | NA |
| Ms. Yvonne Winkler von Mohrenfels | Sr. VP, Gen. Counsel & Sec. | 1966 |
| Mr. Andrew Beer | VP of Marketing & Bus. Devel. | NA |
| Ms. Eileen M. Drury | Sr. VP & Chief HR Officer | 1968 |
Disclaimer - This information, including any data, is sourced from Unicorn Data Services SAS, trading as EOD Historical Data (“EODHD”) on ‘as is’ basis, using their API. The information and data provided on this page, as well as via the API, are not guaranteed to be real-time or accurate. In some cases, the data may include analyst ratings or recommendations sourced through the EODHD API, which are intended solely for general informational purposes.
This information does not consider your personal objectives, financial situation, or needs. Kalkine does not assume any responsibility for any trading losses you might incur as a result of using this information, data, or any analyst rating or recommendation provided. Kalkine will not accept any liability for any loss or damage resulting from reliance on the information, including but not limited to data, quotes, charts, analyst ratings, recommendations, and buy/sell signals sourced via the API.
Please be fully informed about the risks and costs associated with trading in the financial markets, as it is one of the riskiest forms of investment. Kalkine does not provide any warranties regarding the information on this page, including, without limitation, warranties of merchantability or fitness for a particular purpose or use.
US 
AU
UK
CA
NZ
Please wait processing your request...